About Us

Who We Are

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich pipeline of autologous and allogeneic product candidates designed to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality and a lack of effective CAR-T therapies for solid tumors and autoimmune diseases.

Our
History

May. 2025

Gracell was selected as one of the “Biopharma Future Sector 50 Enterprises” by KPMG
Mar. 2025

Gracell was honored with the “Outstanding Achievement Award for Leading Enterprises in 2024”
Sep. 2024

Gracell was honored as the “Best Employer in Greater Suzhou” for the third consecutive year
Jun. 2024

Gracell deepened its strategic collaboration with BioBAY and planned to further expand the production capacity of cell therapy drugs in SuZhou, China
Feb. 2024

Gracell announced the completion of the acquisition by AstraZeneca
Dec. 2023

Gracell entered into a definitive agreement to be acquired by AstraZeneca
Dec. 2023

Gracell won the "Most Valuable Chinese Company Listed in the U.S. in 2023" Award
Nov. 2023

Gracell won the "BioTech Breakthrough Awards: Overall Immunology Solution of the Year"
Aug. 2023

Gracell closed ＄150 million private placement financing, led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX
May. 2023

Gracell expanded clinical evaluation from the therapy area of cancer into autoimmune diseases
Nov. 2022

Gracell Biotechnologies won 2022 Fierce Life Sciences Innovation Award
Dec. 2021

Gracell Biotechnologies was selected for addition to NASDAQ Biotechnology Index
Jan. 2021

Gracell completed IPO and NASDAQ listing, raising $240 million in gross proceeds
Jan. 2021

Suzhou manufacturing facility received Medical Products Manufacturing Certificate from JSMPA
Oct. 2020

Gracell closed series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures, and participation from Vivo, Temasek, LAV, Kington Capital, and Chengdu Miaoji
Aug. 2020

Gracell opened Suzhou GMP manufacturing facility
Feb. 2019

Gracell closed series B funding from Temasek, OrbiMed, Lilly Asia Ventures, Kington Capital, and Chengdu Miaoji
Nov. 2017

Gracell's next-day autologous CAR-T cell manufacturing platform was firstly introduced
Oct. 2017

Gracell opened Shanghai R&D facility
May. 2017

Gracell Biotechnologies was founded by Dr. William Wei Cao and co-founding team

Learn More

You are now leaving Gracell.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

Gracell, a member of the AstraZeneca group provides this link as a service to website visitors. Gracell is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to Gracell’s site or ‘continue’ to proceed

Cancel Continue